natgillin/translations-raw huggingface dataset:
This is to make sure you get the full dose.
Tako boste zagotovili, da boste dobili celoten odmerek.
- The other ingredients are: poly (D,L-lactide-co-glycolide), sucrose and medium chain triglyceride.
- Druge sestavine zdravila so: poli (D,L-laktid koglikolid), saharoza in srednjeverižni triglicerid.
For prolonged-release exenatide treated patients, the incidence of potentially immunogenic injection site reactions (most commonly pruritus with or without erythema) during the 30-week and the two 26-week studies was 9%.
Incidenca možno imunogenih reakcij na mestu injiciranja (najpogosteje pruritis z ali brez eritrema) pri bolnikih, zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, je bila v 30-tedenski in dveh 26-tedenskih študijah 9 %.
Based on hypoglycaemic events that have symptoms consistent with hypoglycaemia with a concomitant glucose value of <54 mg/dl (3 mmol/l) prior to treatment.
Na podlagi hipoglikemij, ki imajo simptome, značilne za hipoglikemijo, ter jih ob tem spremlja koncentracija glukoze pred zdravljenjem < 54 mg/dl (3 mmol/l).
In a 28-week open-label study (oral medication-blinded), Bydureon BCise was compared to sitagliptin and placebo in subjects also using metformin ≥ 1,500 mg daily.
V odprti 28-tedenski študiji (slepljeni za peroralno zdravljenje) so zdravilo Bydureon BCise primerjali s sitagliptinom in placebom pri preiskovancih, ki so uporabljali tudi ≥ 1.500 mg metformina na dan.
If you use more of this medicine than you should, please consult your doctor first as you may need medical treatment.
Če ste uporabili večji odmerek zdravila Bydureon, kot bi smeli Če ste uporabili več tega zdravila, kot bi smeli, se o tem najprej posvetujte z zdravnikom, saj boste morda potrebovali zdravljenje.
Prior to use of the pen, it is recommended that you should be trained by a doctor or diabetes nurse on its proper use.
Priporočljivo je, da vas pred uporabo peresnika zdravnik ali medicinska sestra v diabetološki ambulanti nauči njegove pravilne uporabe.
Common questions and answers.
Pogosta vprašanja in odgovori.
When added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be considered to reduce the risk of hypoglycaemia (see section 4.4).
Kadar dodamo zdravljenju s sulfonilsečnino, moramo premisliti o zmanjšanju odmerka sulfonilsečnine, da zmanjšamo tveganje za pojav hipoglikemije (glejte poglavje 4.4).
This reduction in body weight was seen irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction of -1.9 kg to -5.2 kg with nausea versus -1.0 kg to -2.9 kg without nausea).
To znižanje telesne mase pri bolnikih je bilo neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (povprečno znižanje -1,9 kg do -5,2 kg z navzeo proti -1,0 kg do -2,9 kg brez navzee).
Place the needle, vial connector package, vial, and syringe on a clean, flat surface.
Iglo, paket s povezovalcem viale, vialo in injekcijsko brizgo postavite na čisto, ravno površino.
Subcutaneous injection site nodules were observed frequently in clinical studies, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations.
V kliničnih študijah so se na mestu injiciranja pogosto pojavili podkožni noduli, kar je skladno z znanimi lastnostmi poli (D,L-laktid koglikolid) polimernih mikrosfernih formulacij.
There have been uncommon events of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure and acute renal failure, sometimes requiring haemodialysis.
Z eksenatidom so bili zabeleženi občasni primeri spremenjenega delovanja ledvic, vključno z zvišanjem kreatinina v serumu, okvaro ledvic, poslabšanjem kronične odpovedi ledvic in akutno odpovedjo ledvic, z občasno potrebo po hemodializi.
In postmarketing experiences, cases with injection site abscesses and cellulitis have been reported.
V obdobju trženja zdravila so poročali o abscesih in celulitisu na mestu injiciranja.
• WITHOUT twisting the knob, ROTATE the pen every few taps.
• Peresnik vsakih nekaj udarcev OBRNITE, NE DA BI pri tem zasukali gumb.
Clinical studies with prolonged-release exenatide formulations have indicated improved beta-cell function, using measures such as the homeostasis model assessments (HOMA-B).
Klinične študije z eksenatidom v obliki s podaljšanim sproščanjem so pokazale izboljšano delovanje beta celic, kar je bilo dokazano z metodami kot je ocenjevanje homeostaznega modela (HOMA-B).
The improvement in fasting plasma glucose concentrations was durable through 52 weeks.
Izboljšanje v koncentraciji glukoze v plazmi na tešče je trajalo vseh 52 tednov.
DO NOT try to recap or reuse the needle.
NE POSKUŠAJTE ponovno namestiti pokrovčka na iglo ali igle uporabiti znova.
After discontinuation, the effect of prolonged-release exenatide may continue as plasma levels of exenatide decline over 10 weeks.
Po ukinitvi zdravljenja se lahko učinek eksenatida v obliki s podaljšanim sproščanjem nadaljuje, saj koncentracija eksenatida v plazmi pada naslednjih 10 tednov.
The powder is white to off-white and the solvent is a clear, colourless to pale yellow to pale brown solution.
Prašek je bel do belkast in vehikel je bistra, brezbarvna do bledo rumena oziroma do bledo rjava raztopina.
Patients on pioglitazone gained weight (Table 6).
Bolniki na pioglitazonu so pridobili na telesni masi (Preglednica 6).
The medicine is injected into your skin (subcutaneously).
Zdravilo se injicira pod kožo (subkutano).
The solvent should only be used if it is clear and free of particulate matter.
Vehikel se lahko uporabi le v primeru, ko je bister in ne vsebuje delcev.
- The other ingredients are: - In the powder: poly (D,L-lactide-co-glycolide) and sucrose.
- Druge sestavine zdravila so: - V prašku: poli (D,L-laktid koglikolid) in saharoza.
The pen must be removed from the refrigerator for at least 15 minutes prior to injection.
Peresnik je treba vsaj 15 minut pred injiciranjem vzeti iz hladilnika.
Increased heart rate
Zvišan srčni utrip
INSTRUCTIONS FOR THE USER Read these instructions carefully before use
Pred uporabo natančno preberite ta navodila
Following weekly administration of 2 mg prolonged-release exenatide, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/ml) in 2 weeks with gradual increase in the average plasma exenatide concentration over 6 to 7 weeks.
Ob tedenskem dajanju 2 mg eksenatida v obliki s podaljšanim sproščanjem je povprečna koncentracija eksenatida v dveh tednih presegla minimalno učinkovito koncentracijo (~ 50 pg/ml), s postopnim povečevanjem povprečne plazemske koncentracije eksenatida preko 6 do 7 tednov.
Follow the “Instructions for the User” provided in the carton to inject Bydureon
Sledite “Navodilom za uporabnika”, ki se nahajajo v škatli, za injiciranje zdravila Bydureon.
Needle Top of pen
Igla Vrh peresnika
Rate based on twelve prolonged-release exenatide completed long-term efficacy and safety studies n=2868 total (patients on sulphonylurea n=1002).
Pogostnost na podlagi dvanajstih dokončanih dolgoročnih študij učinkovitosti in varnosti eksenatida v obliki s podaljšanim sproščanjem, n skupaj = 2868, (število bolnikov na sulfonilsečnini n = 1002).
With your thumb, push down the plunger until it stops and hold your thumb in place.
S palcem pritisnite bat navzdol, dokler se ne ustavi in palec držite na mestu.
The need for additional antihyperglycaemic medication was reduced by 33% % with the prolongedrelease exenatide group (exposure-adjusted incidence of 10.5 per 100 pt-year) compared to the placebo group (exposure-adjusted incidence of 15.7 per 100 pt-year).
Potreba po dodatnem antihiperglikemičnem zdravilu se je v skupini z eksenatidom v obliki s podaljšanim sproščanjem zmanjšala za 33 % (za izpostavljenost korigirana pojavnost 10,5 na 100 bolnikov-let) v primerjavi s placebom (za izpostavljenost korigirana pojavnost 15,7 na 100 bolnikov-let).
You should inject this medicine into the skin (subcutaneous injection) of your stomach area (abdomen), upper leg (thigh), or the back of your upper arm. Do not inject into a vein or muscle.
To zdravilo si injicirajte v kožo (subkutana injekcija) področja trebuha (abdomna), zgornjega dela noge (stegno) ali zadnjega dela nadlakti.
Remove the syringe.
Odstranite injekcijsko brizgo.
A. Let your pen come to room temperature.
A. Pustite, da se peresnik ogreje na sobno temperaturo.
If you see white medicine on the sides, bottom or top of the pen window, the medicine is NOT mixed well.
Če vidite belo zdravilo ob straneh, na dnu ali na vrhu okenca peresnika, zdravilo NI dobro premešano.
If a different glucose-lowering treatment is started after the discontinuation of prolonged-release exenatide, consideration should be given to the prolonged release of the product (see section 5.2).
Če se po končanem zdravljenju z eksenatidom v obliki s podaljšanim sproščanjem začne zdravljenje z drugim antidiabetikom, je potrebno upoštevati podaljšan učinek tega zdravila (glejte poglavje 5.2).
Most episodes of nausea were mild to moderate, associated with the initiation of treatment and decreased over time.
Večinoma je bila navzea blaga do zmerna, povezana z uvedbo zdravila ter se je sčasoma zmanjšala.
Do not remove the needle cover yet.
Pokrova igle za zdaj še ne odstranite.
Each dose should be administered in the abdomen, thigh, or the back of the upper arm as a subcutaneous injection immediately after the medicinal product is fully mixed.
Vsak odmerek moramo kot subkutano injekcijo dati v trebuh, stegno ali nadlaket takoj, ko je zdravilo popolnoma premešano.
In the 4 comparator-controlled studies, this reduction in body weight was seen in patients treated with prolonged-release exenatide irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction of -2.9 kg to -5.2 kg with nausea versus -2.2 kg to -2.9 kg without nausea).
V 4 s primerjalnimi zdravili kontroliranih študijah je bilo to znižanje telesne mase pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (povprečno znižanje -2,9 kg do -5,2 kg z navzeo proti -2,2 kg do -2,9 kg brez navzee).
Clinical experience in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min) is limited (see section 5.2).
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic (očistek kreatinina 30 do 50 ml/min) je malo (glejte poglavje 5.2).
The reductions in body weight were sustained at Week 52.
Zmanjšanje telesne mase je bilo po 52 tednih ohranjeno.
Do not throw the container in your household waste.
Vsebnika ne odvrzite med gospodinjske odpadke.
Use your thumb to remove the green cap.
S palcem odstranite zelen pokrovček.
Vial connector
viala povezovalec viale (vial connector)
In two studies prolonged-release exenatide 2 mg once weekly has been compared to immediate-release exenatide 5 mcg given twice daily for 4 weeks followed by immediate-release exenatide 10 mcg given twice daily.
Dve študiji z eksenatidom v obliki s podaljšanim sproščanjem 2 mg enkrat tedensko sta bili primerjani z eksenatidom v obliki s takojšnim sproščanjem 5 µg dvakrat dnevno 4 tedne, čemur je sledil eksenatid v obliki s takojšnim sproščanjem 10 µg dvakrat dnevno.
• Read the Package Leaflet carefully.
• Natančno preberite navodilo za uporabo.
With the other hand, twist the orange connector to remove.
Z drugo roko odvijte oranžni povezovalec in ga odstranite.
Now, hold the vial so the syringe is pointing up.
Sedaj primite vialo tako, da injekcijska brizga gleda gor.
Population pharmacokinetic analysis of renal impaired patients receiving 2 mg prolonged-release exenatide indicate that there may be an increase in systemic exposure of approximately 74% and 23% (median prediction in each group) in moderate (N = 10) and mild (N = 56) renal impaired patients, respectively as compared to normal (N = 84) renal function patients.
Populacijska farmakokinetična analiza bolnikov z okvaro ledvic, ki so prejemali 2 mg eksenatida v obliki s podaljšanim sproščanjem, kaže, da lahko pride do zvišane sistemske izpostavljenosti pri približno 74 % in 23 % (predvideni srednji vrednosti v vsaki skupini) bolnikih z zmerno (n = 10) in blago (n = 56) okvaro ledvic, v primerjavi z bolniki z normalnim (n = 84) delovanjem ledvic.
Use a new injection needle for each injection and dispose of it safely after each use as instructed by your doctor or diabetes nurse.
Za vsako injiciranje uporabite novo injekcijsko iglo in jo po vsaki uporabi varno zavrzite, kot vam je naročil zdravnik ali medicinska sestra v diabetološki ambulanti.
The results of two studies with Bydureon BCise and six long-term clinical studies of prolonged-release exenatide are presented below; these studies comprised 1766 subjects (556 treated with Bydureon BCise), 53% men and 47% women, 304 subjects (17%) were ≥ 65 years of age.
Te študije so vključevale 1766 preiskovancev (556 zdravljenih z zdravilom Bydureon BCise), 53 % moških in 47 % žensk; 304 osebe (17 %) so bile stare ≥ 65 let.
Furthermore, in the clinical studies, patients on a sulphonylurea combination with mild renal impairment had an increased incidence of hypoglycaemia compared to patients with normal renal function.
V kliničnih študijah pri bolnikih z blago okvaro ledvic, ki so jemali kombinacijo s sulfonilsečnino, je bila incidenca hipoglikemije večja v primerjavi z bolniki z normalnim delovanjem ledvic.
Prolonged-release exenatide 2 mg + Insulin glargine
2 mg eksenatida v obliki s podaljšanim sproščanjem + insulin glargin
No pharmacokinetics study of prolonged-release exenatide has been conducted in the paediatric population.
Pri pediatrični populaciji niso izvedli nobenih farmakokinetičnih študij z eksenatidom v obliki s podaljšanim sproščanjem.
The suspension is packaged in a 2-ml Type I glass cartridge, sealed at one end with a (bromobutyl) rubber seal/cap combination (combiseal), and at the other end with a (bromobuty) rubber plunger.
Suspenzija je pakirana v 2-ml vložek iz stekla tipa I, ki je na eni strani zaprt s kombinacijo (brombutilne) gumijaste zapore/pokrovčka (kombinirana zapora) in na drugi strani z (brombutilnim) gumijastim batom.
The following interaction studies have been conducted using 10 mcg immediate-release exenatide but not prolonged-release exenatide formulations:
Sledeče študije medsebojnega delovanja so bile narejene za uporabo 10 μg eksenatida v obliki s takojšnim sproščanjem, in ne za uporabo eksenatida v obliki s podaljšanim sproščanjem:
The powder in one chamber must be mixed with the solvent in the other chamber of the pre-filled pen.
Prašek v enem prekatu je potrebno zmešati z vehiklom v drugem prekatu napolnjenega injekcijskega peresnika.
Hold the pen up straight with the orange cap toward the ceiling.
Držite peresnik pokonci in obrnjen tako, da oranžni pokrovček gleda proti stropu.
1 vial of 2 mg exenatide
1 vialo z 2 mg eksenatida
Lift the vial with the orange connector now attached out of its package.
Dvignite vialo - oranžni povezovalec bo sedaj odstranjen iz ovojnine.
Clinical experience in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min) is limited.
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic (očistek kreatinina 30 do 50 ml/min) je malo.
Fasting lipids Prolonged-release exenatide has shown no negative effects on lipid parameters.
Za eksenatid v obliki s podaljšanim sproščanjem niso ugotovili nobenega neugodnega učinka na parametre lipidov.
For subcutaneous use only
Samo za subkutano uporabo
The absorption properties of exenatide reflect the extended release properties of the prolonged-release exenatide formulation.
Absorpcijske lastnosti eksenatida odražajo podaljšano sproščanje eksenatida v obliki s podaljšanim sproščanjem.
When this medicine is used with a medicine that contains a sulphonylurea, episodes of low blood sugar (hypoglycaemia, generally mild to moderate) can occur.
Pri uporabi tega zdravila sočasno z zdravilom, ki vsebuje sulfonilsečnino, lahko pride do epizod nizkega sladkorja v krvi (hipoglikemije, na splošno blage do zmerno hude).
Pre-filled pen is for single-use only.
Napolnjen injekcijski peresnik je le za enkratno uporabo.
Patients on pioglitazone gained weight (Table 4).
Bolniki na pioglitazonu so pridobili na telesni masi (Preglednica 4).
The dose of your sulphonylurea medicine may need to be reduced while you use this medicine.
Med vašo uporabo tega zdravila boste morda morali znižati odmerek vašega zdravila s sulfonilsečnino.
• hypoglycaemia (low blood sugar) when this medicine is used with a medicine that does not contain a sulphonylurea
• hipoglikemija (nizek krvni sladkor) v primeru uporabe z zdravilom, ki ne vsebuje sulfonilsečnine
Powder poly (D,L-lactide-co-glycolide) sucrose
Prašek poli (D,L-laktid koglikolid) saharoza
However, as renal function generally declines with age, consideration should be given to the patient's renal function (see Renal impairment) (see section 5.2).
Ker pa se delovanje ledvic z leti slabša, je pozornost potrebno posvetiti bolnikovemu delovanju ledvic (glejte Okvara ledvic) (glejte poglavje 5.2).
Hold the syringe near the black dashed Dose Line.
Injekcijsko brizgo držite blizu črne odmerne črte.
There have been spontaneously reported events of acute pancreatitis with prolonged-release exenatide.
Obstajajo tudi spontana poročila o primerih akutnega pankreatitisa pri uporabi eksenatida v obliki s podaljšanim sproščanjem.
You may see a few drops of liquid on the needle or in the cover.
Na igli ali na pokrovčku lahko opazite nekaj kapljic tekočine.
Its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhoea.
Uporabo zdravila pogosto povezujejo z neželenimi učinki na prebavila, vključno z navzeo, bruhanjem in drisko.
In interaction studies of the effect of immediate-release exenatide on digoxin and lisinopril there were no clinical relevant effects on Cmax or AUC, however, a delay in tmax of about 2 h was observed.
V študijah medsebojnega delovanja učinka eksenatida v obliki s takojšnim sproščanjem na digoksin in lizinopril niso ugotovili nobenih klinično pomembnih učinkov na Cmax ali AUC.
Rate based on twelve prolonged-release exenatide completed long-term efficacy and safety studies n = 2868 total.
Pogostnost na podlagi dvanajstih dokončanih dolgoročnih študij učinkovitosti in varnosti eksenatida v obliki s podaljšanim sproščanjem, n skupaj = 2868.
Hold Upright
Ne zamrzujte.
Clinically and statistically significantly more subjects on prolonged-release compared to immediate-release exenatide patients achieved an HbA1c reduction of ≤ 7 % or < 7 % in the two studies (p <0.05 and p ≤0.0001, respectively).
Klinično in statistično značilno več oseb, ki so se zdravile z eksenatidom v obliki s podaljšanim sproščanjem, je v primerjavi z eksenatidom v obliki s takojšnim sproščanjem doseglo znižanje HbA1c ≤ 7 % ali < 7 % v obeh študijah (p < 0,05 in p ≤ 0,0001).
§nominal p-value <0.001.
§nominalni p < 0,001.
Pull the plunger down beyond the black dashed Dose Line.
Bat povlecite navzdol preko s črno označene odmerne črte.
• Refer to the Common questions and answers
• glejte Pogosta vprašanja in odgovori
Fasting lipids The prolonged-release exenatide formulations have shown no negative effects on lipid parameters.
Za eksenatid v oblikah s podaljšanim sproščanjem niso ugotovili nobenega neugodnega učinka na parametre lipidov.
Step 3: Inject your dose
3. korak: Injicirajte odmerek
• hypoglycaemia (low blood sugar) when taken with a medicine that contains a sulphonylurea.
• hipoglikemija (nizek krvni sladkor) v primeru uporabe z zdravilom, ki vsebuje sulfonilsečnino.
For all patients completing the uncontrolled study extension of 7 years (n = 122 of 258 patients included in the extension phase), HbA1c gradually increased over time from Week 52 onwards, but was still reduced compared to baseline after 7 years (-1.5%).
Pri vseh bolnikih, ki so zaključili 7-letno nekontrolirano podaljšano študijo (n = 122 od 258 bolnikov, ki so bili vključeni v podaljšano fazo), se je HbA1c skozi obdobje od 52. tedna naprej postopno povečeval, toda po 7 letih je bil še vedno znižan v primerjavi z izhodiščem (-1,5 %).
Unless a trained person can help to inject this medicine it is not recommended for people who are blind or cannot see well.
To zdravilo ni priporočljivo za slepe in slabovidne osebe, če nimajo na voljo usposobljene osebe za pomoč pri injiciranju.
To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea may be considered (see sections 4.2 and 4.4).
Da se izognemo tveganju za hipoglikemijo, povezano z uporabo sulfonilsečnine, je potrebno razmisliti o zmanjšanju odmerka sulfonilsečnine (glejte poglavji 4.2 in 4.4).
Multi-pack of 3 x (4 single dose kits).
Veliko pakiranje 3 x (4 enoodmerni seti).
B. Twist knob to release injection button.
B. Zasukajte gumb, da boste sprostili gumb za injiciranje.
Keep pushing on the plunger with your thumb until it stops, and hold it in place.
Nadaljujte s pritiskanjem palca na bat, dokler se ne ustavi, ter ga nato držite.
Exenatide slows gastric emptying, thereby reducing the rate at which meal-derived glucose appears in the circulation.
Eksenatid upočasni praznjenje želodca, s čimer zmanjša hitrost, s katero se glukoza iz obroka pojavi v krvnem obtoku.
The concurrent use of prolonged-release exenatide with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied.
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem z derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptil peptidaze-4 ali drugih zaviralcev receptorjev GLP-1 niso preučevali.
In clinical studies of prolonged-release exenatide, approximately 45% of patients had low titre antibodies to exenatide at study endpoint.
Na koncu kliničnih študij z eksenatidom v obliki s podaljšanim sproščanjem je imelo približno 45 % bolnikov nizke titre protiteles proti eksenatidu.
The results of long-term clinical studies of prolonged-release exenatide are presented below; these studies comprised 1356 subjects treated with prolonged-release exenatide, 52% men and 48% women; 230 subjects (17%) were ≥ 65 years of age.
Te študije so vključevale 1356 oseb zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, 52 % moških in 48 % žensk; 230 oseb (17 %) je bilo starih ≥ 65 let.
Insert the needle into your skin (subcutaneously).
Zabodite iglo v kožo (subkutano).
• injection site reactions
• reakcije na mestu injiciranja
In a 28-week double-blind study, prolonged-release exenatide added to insulin glargine alone or with metformin was compared to placebo added to insulin glargine alone or with metformin.
V 28-tedenski dvojno slepi študiji so eksenatid v obliki s podaljšanim sproščanjem, dodan insulinu glarginu samemu ali skupaj z metforminom, primerjali s placebom, dodanem insulinu glarginu samemu ali skupaj z metforminom.
Remove the needle and replace it with the spare needle from your kit.
Odstranite iglo in jo zamenjajte z dodatno iglo, ki jo imate v setu.
INR should be monitored during initiation of prolonged-release exenatide therapy in patients on warfarin and/or cumarol derivatives (see sections 4.4 and 4.8).
Pri bolnikih, ki jemljejo varfarin in/ali derivate kumarola je med uvajanjem zdravljenja eksenatida v obliki s podaljšanim sproščanjem potrebno spremljati vrednosti INR (glejte poglavji 4.4 in 4.8).
Remember: You must take your injection of Bydureon immediately after mixing it.
Zapomnite si: Injekcijo Bydureon morate uporabiti takoj po mešanju.
The concurrent use of prolonged-release exenatide formulations with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied.
Sočasne uporabe eksenatida v oblikah s podaljšanim sproščanjem z derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptil peptidaze-4 ali drugih zaviralcev receptorjev GLP-1 niso preučevali.